# YL201

Source: https://onco.cc/drugs/yl201/  
OnCo record `yl201` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

YL201 is an experimental antibody-drug conjugate from MediLink Therapeutics (Suzhou) in phase 3 trials for nasopharyngeal carcinoma, non-small-cell lung cancer and small-cell lung cancer, aimed at B7-H3.

## Summary

YL201 is an antibody-drug conjugate developed by MediLink Therapeutics (Suzhou). Its target is B7-H3 (the sponsor names B7-H3). ClinicalTrials.gov describes the intervention as: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle. It is the investigational product in 9 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06629597 (A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)), NCT06612151 (A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）) and NCT07739758 (A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer), in nasopharyngeal carcinoma, non-small-cell lung cancer, small-cell lung cancer and prostate cancer. The largest, NCT06057922, plans to enrol 990 participants with primary completion expected 2026-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: Tam-Peli; Tambotatug Pelitecan
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Antibody-drug conjugate directed at B7-H3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of YL201: https://clinicaltrials.gov/search?intr=YL201

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Recurrent and metastatic nasopharyngeal carcinoma](https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)
- trials: [A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC](https://onco.cc/trials/nct06241846/), [A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)](https://onco.cc/trials/taishan-301/), [A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）](https://onco.cc/trials/nct06612151/), [A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors](https://onco.cc/trials/nct07208773/), [A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07407933/), [A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07739758/), [A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.](https://onco.cc/trials/nct07258979/), [A Study of YL201 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05434234/), [A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based](https://onco.cc/trials/nct07803783/), [A Study YL201 in Patients With Selected Advanced Solid Tumors](https://onco.cc/trials/nct06057922/)

---
JSON: https://onco.cc/api/v1/entities/yl201.json